Literature DB >> 15744241

Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation.

Bipin N Savani1, Aldemar Montero, Colin Wu, Nene Nlonda, Elizabeth Read, Cynthia Dunbar, Richard Childs, Scott Solomon, A John Barrett.   

Abstract

Between July 1997 and August 2004, 146 consecutive patients with hematologic malignancies received a T cell-depleted peripheral blood stem cell transplant from an HLA-identical sibling by using total body irradiation (TBI) and cyclophosphamide conditioning regimens. Eighty-five patients received 13.6 Gy of TBI with no lung shielding, and 61 received lung shielding (total lung dose, 6-12 Gy). Ninety-four patients (65.5%) had standard-risk disease; the remainder had more advanced disease or unfavorable diagnoses. Of the 21 transplant-related deaths, 14 were from pulmonary causes (10 idiopathic pulmonary syndromes and 4 from infection) that occurred at a median of 90 days (range, 23-238 days) after transplantation. Independent risk factors for pulmonary transplant-related mortality (PTRM) were pretransplantation diffusion capacity for carbon monoxide (relative risk, 5.7 for diffusion capacity for carbon monoxide <85%), smoking (relative risk, 5.0), and CD34 cell dose (relative risk, 9.4 for a CD34 dose of <5 x 10(6) cells per kilogram). Patients receiving lung shielding had significantly lower PTRM (3.3% versus 14.1%; P = .02) and better overall survival (70% +/- 6% versus 52% +/- 5%; P = .04), but lung shielding was not a significant independent factor for determining PTRM. These results suggest that pulmonary mortality after TBI-based preparative regimens is predictable and that higher CD34 cell doses can reduce the risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15744241     DOI: 10.1016/j.bbmt.2004.12.328

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  18 in total

1.  Transforming growth factor-β induces microRNA-29b to promote murine alveolar macrophage dysfunction after bone marrow transplantation.

Authors:  Racquel Domingo-Gonzalez; Carol A Wilke; Steven K Huang; Yasmina Laouar; Jeanette P Brown; Christine M Freeman; Jeffrey L Curtis; Gregory A Yanik; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-31       Impact factor: 5.464

2.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.

Authors:  Christopher C Dvorak; Clarisa R Gracia; Jean E Sanders; Edward Y Cheng; K Scott Baker; Michael A Pulsipher; Anna Petryk
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

3.  Tobacco smoking is associated with infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation.

Authors:  R Hanajiri; K Kakihana; T Kobayashi; N Doki; H Sakamaki; K Ohashi
Journal:  Bone Marrow Transplant       Date:  2015-05-18       Impact factor: 5.483

4.  New Insights Into Multicenter PICU Mortality Among Pediatric Hematopoietic Stem Cell Transplant Patients.

Authors:  Matt S Zinter; Christopher C Dvorak; Aaron Spicer; Morton J Cowan; Anil Sapru
Journal:  Crit Care Med       Date:  2015-09       Impact factor: 7.598

5.  How I treat late effects in adults after allogeneic stem cell transplantation.

Authors:  Bipin N Savani; Michelle L Griffith; Shubhada Jagasia; Stephanie J Lee
Journal:  Blood       Date:  2010-12-30       Impact factor: 22.113

6.  Cigarette smoking and outcomes after allogeneic hematopoietic stem cell transplantation.

Authors:  Betty T Tran; Abigail Halperin; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2011-03-29       Impact factor: 5.742

Review 7.  Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

Authors:  Pawel Muranski; Andrea Boni; Claudia Wrzesinski; Deborah E Citrin; Steven A Rosenberg; Richard Childs; Nicholas P Restifo
Journal:  Nat Clin Pract Oncol       Date:  2006-12

8.  Management of Acute Respiratory Failure in Patients With Hematological Malignancy.

Authors:  Rakesh Vadde; Stephen M Pastores
Journal:  J Intensive Care Med       Date:  2016-07-07       Impact factor: 3.510

9.  The impact of smoking on outcomes among patients undergoing hematopoietic SCT for the treatment of acute leukemia.

Authors:  S L Ehlers; D A Gastineau; C A Patten; P A Decker; S M Rausch; J R Cerhan; W J Hogan; J O Ebbert; L F Porrata
Journal:  Bone Marrow Transplant       Date:  2010-05-17       Impact factor: 5.483

10.  Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.

Authors:  S Dirou; F Malard; A Chambellan; P Chevallier; P Germaud; T Guillaume; J Delaunay; P Moreau; B Delasalle; P Lemarchand; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.